DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

BACKGROUND: Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with AML ≥65 years marks the potential for hypomethylating agents in elderly AML. Nevert...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Grishina, Olga, Schmoor, Claudia, Döhner, Konstanze, Hackanson, Björn, Lubrich, Beate, May, Annette M., Cieslik, Caroline, Müller, Michael J., Lübbert, Michael
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2015
主題:
Study Protocol
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4443550/
https://ncbi.nlm.nih.gov/pubmed/26008690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1432-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料